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REVIEW RETURNED
13-Apr-2018
GENERAL COMMENTS
Statistical Review I am not entirely satisfied that the statistical analyses are above reproach and there is some confusion and lack of clarity in the methods and possibly some errors. However, the data are very valuable and I would encourage the authors to look at their analyses again, and specifically follow up my comments in item (14). 1. The stated objective is to determine whether the time to event (infection) is related to demographic differences (risk factors) such as age, sex, patient type and comorbidities. This is a reasonable aim and the large data set can answer this question well. However, there is confusion (e.g. in the statement of the primary outcome in the abstract) about whether the catheter total 'dwell-time' is also being considered as a risk factor. This is a standard survival model set-up and each day (or each moment in time) will be modelled as having a hazard for occurrence of the infection event. If we record the number of catheter-days (the survival time) for each patient and then divide the patients into two groups, those with and without an infection at the end of their survival time then, inevitably, those with an infection with have had a longer average survival time than those without an infection. Showing a difference in average survival time between these two groups (e.g. in Table 1 ) and in the Results is only showing something which is inevitable.
(2) For the survival analyses (Kaplan-Meier and Cox proportional hazards model) the dwell-time (catheter-days) is defined as the time from insertion of the catheter to either the time of first infection or the time of removal of the catheter for a patient without an infection whichever is the first to occur. Any catheterisation with 2 days' dwell-time or less is removed from the survival analysis and that is understandable given the definition of a CAUTI. The Cox model will be valid even though all the survival times exceed 2 days because the hazard function is non-parametric. The catheterizations of 2 days or fewer could have been included in the data but with the proviso that all these times provided no event. It may have been simpler when describing the methodology.
(3) Duration of catheterization in Table 1 : is that the actual duration from insertion to removal of the catheter or is it time as defined for the Cox regression/Kaplan-Meier analyses? As noted above, if the latter it will inevitable be on average longer for those getting an infection.
(4) CVA tenderness (Introduction) -define CVA. Also EHR, define on first use.
(5) Statistical analysis section. The chi-squared test and the t-test were used to make an unadjusted comparison between catheterizations associated with and without infection and these results are shown in Table 1 .
(6) The methods section does mention the medical versus surgical comparison mentioned elsewhere and this is not in Table 1 .
(7) There were 49,298 patients and 62,692 catheterizations. So, clearly, many patients are included more than once within the catheterization data. So those catheterizations on the same patient will not be independent catheterizations. A patient who gets an infection at one catheterization would be more likely to get an infection on another occasion. This is ignored in the analysis and it does at least require some comment and justification if the lack of independence is not going to be accounted for in the modelling which currently it is not. 
Thanks for inviting me to review this manuscript. The aim of this manuscript was to identify risk factors for catheter-associated urinary tract infections. The author team used an impressive retrospective cohort identified from electronic health records. However, I have the following major concerns in the method and results sections. In addition, can the author team follow the STROBE guideline to revise their manuscript? I will suggest to revise this manuscript and re-submit it again.
1. The study design: Would it be better to use the casecontrol design rather than cohort? 2.
Review of electronic health record nursing documents-can they state the selection process of infections associated to catheters? A selection of ICD codes? What did they mean by "CAUTI events were matched to respective IUC data based on patients' medical record number and admission date"? What happened if patient's records in both sources were not matched? How long is one IUC period? 3.
Statistical analysis: How much power does this study had to identify factors associated with CAUTI? What did they mean by "the EHR data were analysed to assess the effect of the catheter duration on CAUTI development"? I thought that HER data was also used to identify other risk factors and can explain the difference in the CAUTI development by demographics? Did they check the Normal distribution assumption? 4.
Survival analysis: Cox proportional hazards model-did they check the proportion hazard assumption?
5.
Charlson index-Can they justify reasons why not using the overall Charlson index score rather than using each Charlson comorbidity as a risk factor separately? 6.
Outcome-event free survival: can the author team describe how they define the exposure time window and gap between each time window more details? CAUTI could be a repeated event. How did they define a CAUTI as a new event or a repeated event within the same time period? 7.
Can they explain how exactly they assess the risk factors for CAUTI between two populations? Was age included as a covariate in the Cox Hazard model? 8.
Missing data-was there any missing data? How did they deal with missing data?
Results: 9.
Can the author team provide a flow chart to explain how 49.298 patients were identified in the EHR database? 10.
Is IUC normally distributed? If not, they should report median (IQR) rather than mean(SD).
11.
Catheterization and CAUTI rate-what was the method applied here? Can they provide confidence interval of the rate? 12.
Table 1-I am not sure whether t-test is the appropriate method here as these variables might not be normally distributed. In addition, it would be better to choose how they would like to the variable of age-continuous or categorical? Is N for the number of people developed CAUTI or the number of CAUTI events? If it is the latter one, the analysis applied in Table 1 cannot be appliedpeople with repeated CAUTI events would count in multiple times in Table 1 analysis.
13.
What was the method used when reporting "females were 1.8 times more likely to develop…."? 14.
Time-to-event analysis: they really need to describe methods used in the method section before reporting results? What was the objective of reporting non-linear cumulative CAUTI rate? If they want to test the linearity of the trend? What was the method? 15.
Disease free survival results: can the author team re-write results using more appropriate academic writing style-please do not report using "1.45x" to refer to times more". In addition, please always say what the figure is? Is it hazard ratio? You should always report the confidence interval when reporting the point estimate.
VERSION 1 -AUTHOR RESPONSE Response to Reviewers Reviewer 1
Another important point to mention is that the authors used the CDC definitions and not the ICD-9 or ICD-10 definition (or another EHR code) to define CAUTI. These code have a low sensitivity for detecting CAUTI cases. It will be a really big issue, once the NHSN CAUTI metric and ICD-10-CM "CAUTI-like code" produce widely discrepant results. The date of the event is an important element used to meet an NHSN site-specific infection criterion, including CAUTI, and that is one reason that administrative data fail to accurately identify cases of healthcare associated infection. This is a very good observation with which we agree completely. Claims data are problematic to use in these types of analyses, that is why we opted to use the CDC definition. We have emphasized this point in the Methods section.
Reviewer 2
This manuscript is well-written. The large number of patients that were included in this retrospective study increases the likelihood that the results can be meaningfully applied to patients who are admitted at acute care hospitals throughout the country. The statistical analysis should be reviewed by a specialist, and if the results of this study are corroborated, then the manuscript should be accepted for publication.
Thank you, we agree that the large number of patients in the study is a strength of the work. We have read the revisions requested by the statisticians and have modified the manuscript significantly to comply with their requests for revisions.
Reviewer 3
1. The stated objective is to determine whether the time to event (infection) is related to demographic differences (risk factors) such as age, sex, patient type and comorbidities. This is a reasonable aim and the large data set can answer this question well. However, there is confusion (e.g. in the statement of the primary outcome in the abstract) about whether the catheter total 'dwell-time' is also being considered as a risk factor. This is a standard survival model set-up and each day (or each moment in time) will be modelled as having a hazard for occurrence of the infection event. If we record the number of catheter-days (the survival time) for each patient and then divide the patients into two groups, those with and without an infection at the end of their survival time then, inevitably, those with an infection with have had a longer average survival time than those without an infection. Showing a difference in average survival time between these two groups (e.g. in Table 1 ) and in the Results is only showing something which is inevitable.
Thank you, you are correct. We see how the stated objective in the original manuscript did not match well with the way that the results were presented and described. We have rewritten the methods, presented results in a different way, and edited Table 1 in an effort to remove the confusion caused in the earlier version of the manuscript.. We thank the reviewer for suggesting that we include dwell times less than 2 days in the survival model. However, because by definition CAUTIs do not occur in the first 2 days of catheterization (i.e. UTI occurring in this period is not categorized as CAUTI), in the tradeoff between a model that is simpler to explain (including the first 2 days) and a model that is more targeted and useful (only focusing on days 3 and after), we prefer to sacrifice the simplicity.
Thank you, you are correct that the average would be longer for those patients who had an infection. We have addressed this issue by modifying our language in the paper and removed the duration of catheterization as a row in Table 1 . We have added the definitions of each abbreviation on the first use.
(5) Statistical analysis section. The methods section does mention the medical versus surgical comparison mentioned elsewhere and this is not in Table 1 .
We have modified Table 1 to include medical vs. surgical comparison and Charlson Comorbidity score.
(7) There were 49,298 patients and 62,692 catheterizations. So, clearly, many patients are included more than once within the catheterization data. So those catheterizations on the same patient will not be independent catheterizations. A patient who gets an infection at one catheterization would be more likely to get an infection on another occasion. This is ignored in the analysis and it does at least require some comment and justification if the lack of independence is not going to be accounted for in the modelling which currently it is not.
We added this as a limitation of our study in the Discussion section. The reviewer is correct to say that some of the data points may not be independent, and that patient-level data may contribute to the chance of infection. While we tried to account for these patient-level factors through an adjusted model, it is likely that there are unmeasured patient-level factors that were not adjusted for in our model. Table 1 shows NS for not significant. A similar comment applies for 65+ which has a p-value of about 0.01 and is certainly significant. Now it may be that a chisquared test was carried out for all the age groups together and that the 0.02 on the 0-17 line applies to that test. In which case the separate NS values shown against each age group need to be removed. The percentages for sex do not look correct. 100*537/884 = 60.7% and 100*30069/61808=48.6% and the tables shows different values to these. It is likely that a number of records have sex and/or age missing and this may account for the discrepancies. But if this is the case, it would be helpful to know. It looks like there are about 500 ages missing from the No CAUTI group.
(8) This leads on to
Thank you very much for finding these inconsistencies. We have modified Table 1 to correct the overlap, and the numbers now reflect a modified patient population of patients with only full records.
(10) Results -CAUTI rates. It would be helpful to be told the total number of catheter-days. The overall rate suggests this is about 539,000 catheter-days in total and similarly useful to know for the 0-17 and 18+ age groups. The rates for the two age groups is quoted as nonstatistically different and this is difficult to believe and is contradictory to the statement in the next paragraph which references Table 1. It may be the error in the p-value for 0 -17 year olds that has produced this contradiction.
We have added the total cather days overall and within each age group to the paper. For the full population of catheterizations (used only to report CAUTI rate per 1000 catheter days) we have 540,494 catheter days. The pediatric population (0-17 years of age) had a total of 23,531 catheter days and a CAUTI rate of 2.08 [95% CI: 1.56-2.78] per 1000 catheter-days. The adult population (18+ years of age) had a total of 517,335 catheter days and a CAUTI rate of 1.61 [95% CI: 1.51-1.73] per 1000 catheter-days, a non-statistically significant difference (p=0.098) because of the overlapping confidence intervals.
For the filtered population used for the time-to-event analyses, the total catheter days is 381,951 (16,254 for pediatric patients and 365,697 for adult patients).
(11) 'Females were 1.8 times more likely to develop CAUTI than males'. I think the value is closer to 1.6. Values in Table 1 show 537 females and hence 347 males developed a CAUTI (537+347=884). 30,069 females and 31,171 males (assuming the 49.1% is correct) had no CAUTI. This gives a relative risk of (537/(537+30069))/(347/(347+31171)) = 1.59 and an odds ratio of 1.60. I have not looked at the other reported relative risks but these should be checked.
This statistic reported is a hazard ratio, we have clarified this in the text and modified it to reflect the hazard for males so it lines up with the new Figure 4 . However, as the hazard for males is 0.56, the hazard for females is 1/0.56 = 1.8. We appreciate the comment and have replaced the first figure in the paper with the Kaplan-Meier curve for the full patient population. We have also added the hazard ratios resulting from the Cox model in a new figure to help the interpretation of these models.
(14) The authors express interest in looking at dwell-time of the catheter as a risk factor for infection and, as explained above, we know 'a priori' that the longer a catheter was in place the higher the probability that the patient will have got an infection. This is self-evident. However, what is not self-evident is how the hazard for getting an infection each day varies as a function of time since catheter was put in. For this the authors should obtain the daily hazard function using Kaplan-Meier estimation and show this in a table or a plot. They can get this for all the data or for subsets of interest such as males and females separately. The hazard for day 7 will be the chance of getting an infection on day 7 given that the patient has not yet had an infection so far. Looking at the shape of the daily hazard will be very informative. If the hazard is constant it would mean that a patient has no worse a chance of getting an infection on day 7 (catheter already in place for 6 days) than he would have had the catheter been in place for, say, 4 days. If one knew this, then there would be no reason to remove the catheter based on risk to patient and the decision could be made on a day to day basis. Does the daily hazard go up or go down or stay constant? If the hazard goes down then we could say, if you have had no infection in, say 10 days, you are increasingly unlikely to get one if we leave it in. If the hazard rockets at day 8 then one would know 'best to get catheter out by day 8.' These data should be very valuable in answering these questions and I would encourage the authors to look at this for a more useful study.
Thank you, this comment helped us re-examine our graphs and results that we presented. We have calculated the instantaneous daily hazard rates using the Kaplan-Meier estimates and provide a raw and smoothed representation of them in Figure 2 . From left to right, the number of patients with that many days of catheterization decreases, and hence the confidence-interval for the smoothed model widens. The B-spline smoothing model estimates that instantaneous hazard to be the highest at around 40 days.
(15) Some further results are given in the Discussion and maybe these should be moved to the Results section.
We chose to present the RCA results in the Discussion section as these analyses were completed post-hoc. RCAs are only done in particular cases (most often for CAUTIs contracted in ICUs) and for operational reasons. As the CAUTIs are not systematically completed for every CAUTI we chose to present our findings as an anecdotal piece of evidence in the Discussion instead of the in the body of the Results section.
Reviewer 4
In addition, can the author team follow the STROBE guideline to revise their manuscript?
We have completed the STROBE checklist for this paper and revised the manuscript to align with the STROBE guidelines.
The study design: Would it be better to use the case-control design rather than cohort?
While case-control design is generally preferred for rare events, and CAUTIs are indeed rare events, this is mainly because cohort studies are expensive to execute, and not because they are of less methodological rigor compared to case-control studies. In our case, however, conducting a historical cohort study would not be expensive, due to the availability of the data through the EHR. The cohort design has one additional advantage in that it includes all patients from the cohort, while a casecontrol design would require restricting the controls to a smaller subset that are matched to cases. This would not only reduce statistical power, but also would introduce any unknown biases caused by matching (which is always imperfect). In the light of this information, we decided to use a historical cohort design.
2. Review of electronic health record nursing documents-can they state the selection process of infections associated to catheters? A selection of ICD codes? What did they mean by "CAUTI events were matched to respective IUC data based on patients' medical record number and admission date"? What happened if patient's records in both sources were not matched? How long is one IUC period?
Catheterizations (IUC durations) were extracted from nursing flow sheet documentation. CAUTI presence was extracted from Infection Prevention and Control logs as they are manually determined after detailed review of EHR data. Both flowsheet documentation and CAUTI presence logs contained patient MRN and admission date, these two identifiers were used to link the catheterization with the CAUTI data. There were many people who had IUC data but not CAUTI presence data, these patients were patients with no CAUTI event.
3. Statistical analysis: How much power does this study had to identify factors associated with CAUTI? What did they mean by "the EHR data were analysed to assess the effect of the catheter duration on CAUTI development"? I thought that HER data was also used to identify other risk factors and can explain the difference in the CAUTI development by demographics? Did they check the Normal distribution assumption?
In planning this work we elected to forgo a power calculation because the patient population is so large and the cost of such an observational study is small relative to a typical clinical trial. The results of our analysis suggest that we are well powered to detect the differences that we report. EHR data was used to capture all the risk factors (both dwell-time as well as the confounders). We have revised the text and replaced that sentence altogether.
Survival analysis: Cox proportional hazards model-did they check the proportion hazard assumption?
Yes, the proportional hazard assumption was checked and it holds. We have included this statement in the manuscript.
Charlson index-Can they justify reasons why not using the overall Charlson index score rather than using each Charlson comorbidity as a risk factor separately?
We actually did use the overall score as well, but it was non significant. We have clarified this point in the text. As the score is an aggregate of the risk factors and since we have the factors we can use them all to get more granular information.
6. Outcome-event free survival: can the author team describe how they define the exposure time window and gap between each time window more details? CAUTI could be a repeated event. How did they define a CAUTI as a new event or a repeated event within the same time period?
If multiple CAUTI events occurred during one IUC period, only the earliest CAUTI was included in our analysis. However if there was a reinsertion, this was considered a new IUC period and therefore a CAUTI during this new period would be eligible for the study. We have added this information to the methods section of the manuscript.
Can they explain how exactly they assess the risk factors for CAUTI between two populations?
We revised the Methods section to better explain how the survival model was created. We used age, among other potential confounders (such as sex, patient type, and comorbidities) as covariates in the model.
Was age included as a covariate in the Cox Hazard model?
Yes, age was included as a covariate in the Cox model. All of the factors included in the model are listed in the methods section. They are: age, sex, patient type (medical vs. surgical), the Charlson Comorbidity Index, and the presence or absence of the 17 comorbidities that are input into the Charlson score.
Missing data-was there any missing data? How did they deal with missing data?
Yes, there were missing data. A total of 1,688 patients were removed because of their missing data (missing either age, sex, patient type, ICD-9s for defining comorbidities). This is new.
Results: Can the author team provide a flow chart to explain how 49.298 patients were identified in the EHR database?
We used t-test because the sheer size of the data set would satisfy the Central Limit Theorem. To reassure the reviewer, we repeated the time-independent analyses using a non-parametric Wilcoxon rank-sum test as well, and the results remained unchanged in terms of direction and significance.
We elected to leave age in both continuous and categorical form to demonstrate where the ages are most different in terms of their CAUTI rates.
We have revised the legend for Table 1 to clarify that the unit of analysis for this table is catheterizations, not patients. Therefore, it is intentional (and we believe, desirable) that a patient with multiple catheterizations would be counted multiple times in this table.
14. What was the method used when reporting "females were 1.8 times more likely to develop...
."?
This statistic reported is a hazard ratio, we have clarified this in the text and modified it to reflect the hazard for males so it lines up with the new Figure 4 . However, as the hazard for males is 0.56, the hazard for females is 1/0.56 = 1.8.
15
. Time-to-event analysis: they really need to describe methods used in the method section before reporting results? What was the objective of reporting non-linear cumulative CAUTI rate? If they want to test the linearity of the trend? What was the method?
We have significantly modified the methods section to explain which methods were used for which results and why.
16. Disease free survival results: can the author team re-write results using more appropriate academic writing style-please do not report using "1.45x" to refer to times more". In addition, please always say what the figure is? Is it hazard ratio? You should always report the confidence interval when reporting the point estimate.
We have rephrased the sentences as described. We have made sure to explain that these numbers are hazard ratios and we report the confidence intervals in the figure and text as well.
VERSION 2 -REVIEW

REVIEWER
Alexandre Marra University of Iowa Hospitals and Clinics, Iowa City IA, Hospital Israelta Albert Einstein, Sao Paulo, Brazil REVIEW RETURNED 13-Sep-2018
GENERAL COMMENTS
I am ready to accept this paper to be published. This paper improved after the reviewers' comments with more clear thoughts.
Thanks the opportunity to participate in this review. I am sure that this manuscript will help our physicians to make better decisions to prevent CAUTI in our patients. 
REVIEWER
VERSION 2 -AUTHOR RESPONSE
Thank you to the editor and the reviewers for their help in reviewing the manuscript.
We have added the name of the ethical review board that approved our study in the methods section.
Additionally, we have added the missing phrase of "at 30 days" to page 7.
